drugset / Trial / NCT07197827
A Study of YL242 in Subjects With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
Timeline
- Start
- 2025-09-22
- Primary completion
- 2028-09
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LV | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | YL242 | Unknown | — | Intravenous |
| Subject | fluorouracil | Small molecule | — | Intravenous |